| Pharmaceutical Information |
| Drug Name |
Amsacrine |
| Drug ID |
BADD_D00137 |
| Description |
Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects. |
| Indications and Usage |
For treatment of acute myeloid leukaemia. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XX01 |
| DrugBank ID |
DB00276
|
| KEGG ID |
D02321
|
| MeSH ID |
D000677
|
| PubChem ID |
2179
|
| TTD Drug ID |
D0G9YH
|
| NDC Product Code |
Not Available |
| UNII |
00DPD30SOY
|
| Synonyms |
Amsacrine | Cain's Acridine | Cain Acridine | Cains Acridine | meta-AMSA | meta AMSA | AMSA | m-AMSA | Amsidyl | SN-11841 | SN 11841 | SN11841 | NSC-156303 | NSC 156303 | NSC156303 | NSC-249992 | NSC 249992 | NSC249992 | Amsidine | Amsacrina | AMSA P-D | AMSA P D | AMSA PD | NSC-141549 | NSC 141549 | NSC141549 |
|
| Chemical Information |
| Molecular Formula |
C21H19N3O3S |
| CAS Registry Number |
51264-14-3 |
| SMILES |
COC1=C(C=CC(=C1)NS(=O)(=O)C)NC2=C3C=CC=CC3=NC4=CC=CC=C42 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
